A bold vision and a transformative approach, driven by our deep expertise.
Our Management, Board of Directors, and Scientific Advisory Board are comprised of world-class GI and autoimmune experts. Most with the experience and knowledge gained at large pharmaceutical companies and adapted to our unique culture of innovation and agility. All united by their desire to improve the treatment paradigm by developing targeted therapies.
The scientific minds informing our innovative approach
Our Scientific Advisory Board combines years of medical and discovery experience, clinical research activity, and regulatory expertise.
Scientific Advisory Board
Bruce E. Sands, M.D.
Dr. Bruce E. Sands is the head of the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai in New York, NY. He also serves as the Dr. Burrill B. Crohn’s Professor and Chief of Gastroenterology at Mount Sinai. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn’s & Colitis Center at Massachusetts General Hospital in Boston, Massachusetts, where he also served as the hospital’s Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School. He is a fellow of the American College of Gastroenterology and the American Gastroenterological Association and is reviewer for the New England Journal of Medicine. Dr. Sands received his medical degree at Boston University School of Medicine and completed a residency in internal medicine at the Hospital of the University of Pennsylvania. He then completed clinical and research fellowships at Massachusetts General Hospital. In 2001, Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Stephan Targan, M.D.
Donna Griebel, M.D.
Dermot McGovern, M.D., Ph.D.
Brian G. Feagan, M.D.
Mitchell Kronenberg, Ph.D.
Laurens Kruidenier, Ph.D.